Michael Massaro

Vtesse, Inc. provides novel drugs for life-threatening rare diseases. It developed VTS-270, a modified form of cyclodextrin that has been evaluated in preclinical and clinical studies at institutes within the National Institutes of Health (NIH) to treat patients with Niemann-Pick Disease Type C (NPC). The firm is working with the NIH and other leading academic centers to advance clinical study of VTS-270 for NPC, and to conduct pre-clinical discovery and development of other novel drugs for NPC and other LSDs. The company was founded by Ben Machielse in 2015 and is headquartered in Gaithersburg, MD.

Part of Marvell Technology, Inc., ClinTrials Research, Inc. engages in clinical research organization. The company is based in Cary, NC. ClinTrials Research was acquired by Indigo Acquisition Corp on April 03, 2001 for $110.42 million.

MedImmune Vaccines, Inc. develops, manufactures and markets live vaccines. Its developed vaccine is inhaled FluMist. The company is located in Mountain View, CA

Kendle International LLC provides research and development services to biopharmaceutical companies by offering value-added clinical research services and proprietary information technology. The company was founded in 1981 and is headquartered in Cincinnati, OH.

Wound Solutions Ltd. develops wound healing care therapies. Its products and technologies provide diagnostic information to medical practitioners to enable improved healing programmes. The company’s current products ensure patients to wear their compression bandages and guide them to follow treatment programmes that improve time to healing. It specializes in medical devices, wound care, medical technology and venous leg ulcers treatments. The company was founded by Julian Michael Edward Lee and Richard Adam Nagle on June 11, 2003 and is headquartered in London, GB.